Success Metrics

Clinical Success Rate
81.3%

Based on 13 completed trials

Completion Rate
81%(13/16)
Active Trials
5(17%)
Results Posted
54%(7 trials)
Terminated
3(10%)

Phase Distribution

Ph phase_1
3
10%
Ph phase_3
3
10%
Ph phase_4
10
34%
Ph not_applicable
5
17%
Ph phase_2
4
14%
Ph early_phase_1
1
3%

Phase Distribution

4

Early Stage

4

Mid Stage

13

Late Stage

Phase Distribution26 total trials
Early Phase 1First-in-human
1(3.8%)
Phase 1Safety & dosage
3(11.5%)
Phase 2Efficacy & side effects
4(15.4%)
Phase 3Large-scale testing
3(11.5%)
Phase 4Post-market surveillance
10(38.5%)
N/ANon-phased studies
5(19.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

68.4%

13 of 19 finished

Non-Completion Rate

31.6%

6 ended early

Currently Active

5

trials recruiting

Total Trials

29

all time

Status Distribution
Active(7)
Completed(13)
Terminated(6)
Other(3)

Detailed Status

Completed13
Terminated3
Withdrawn3
Recruiting3
unknown2
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
29
Active
5
Success Rate
81.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (3.8%)
Phase 13 (11.5%)
Phase 24 (15.4%)
Phase 33 (11.5%)
Phase 410 (38.5%)
N/A5 (19.2%)

Trials by Status

terminated310%
enrolling_by_invitation13%
unknown27%
not_yet_recruiting13%
withdrawn310%
active_not_recruiting27%
recruiting310%
suspended13%
completed1345%

Recent Activity

5 active trials
Showing 5 of 29
terminatedphase_4

Angiotensin II for Distributive Shock

NCT04904562
not_yet_recruitingphase_4

Mechanistic Assessment of Norepinephrine Therapy vs. Angiotensin-II in Septic Shock

NCT06746753
active_not_recruitingphase_2

Angiotensin II in Liver Transplantation

NCT04901169
completedphase_4

Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock

NCT05824767
recruitingphase_4

ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery)

NCT06487585
View all 29 trials

Clinical Trials (29)

Showing 20 of 29 trialsScroll for more
NCT04904562Phase 4

Angiotensin II for Distributive Shock

Terminated
NCT06746753Phase 4

Mechanistic Assessment of Norepinephrine Therapy vs. Angiotensin-II in Septic Shock

Not Yet Recruiting
NCT04901169Phase 2

Angiotensin II in Liver Transplantation

Active Not Recruiting
NCT05824767Phase 4

Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock

Completed
NCT06487585Phase 4

ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery)

Recruiting
NCT01426529Phase 1

Caveolin-1 and Vascular Dysfunction

Active Not Recruiting
NCT00962949Phase 1

The Renin-Aldosterone Axis in Postural Tachycardia Syndrome

Completed
NCT04592744Phase 4

Angiotensin 2 for AKI After OLT

Enrolling By Invitation
NCT03733145Phase 4

Angiotensin II in General Anesthesia

Completed
NCT06615102Phase 3

Reducing Cardiac-surgery Associated Acute Kidney Injury Occurence by Administering Angiotensin II

Recruiting
NCT06234592Not Applicable

The Effect of Vasopressor Therapy on Renal Perfusion in Septic Shock

Recruiting
NCT06157580Early Phase 1

Balance of Angiotensin II Receptors in Vessel Function After Preeclampsia

Completed
NCT04558359Phase 4

Renin and Renal Biomarker Response to Angiotensin II

Completed
NCT01393782Phase 1

Intravenous AII for the Treatment of Severe Hypotension in High Output Shock: A Pilot Study

Completed
NCT05193370Phase 4

Angiotensin II vs. Vasopressin in Septic Shock

Withdrawn
NCT04048707Phase 2

Angiotensin 2 for Hepatorenal Syndrome

Withdrawn
NCT05199493Phase 3

Reducing Acute Kidney Injury Occurence by Administering Angiotensin II

Completed
NCT04529005Phase 4

Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant Recipients

Completed
NCT01511042

Vascular Dysfunction in Diabetes: Genes and Hormones

Terminated
NCT04408326

Efficacy and Safety of Angiotensin II Use in Coronavirus Disease(COVID)-19 Patients With Acute Respiratory Distress Syndrome

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
29